On Wednesday, Jim Cramer, the host of Mad Money, shared his concerns about President Donald Trump’s approach to trade and its ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) had a banner year in 2024. The company's sales surged 32% to over $45 billion ...

After starting 2024 strong, Eli Lilly (NYSE: LLY) did not perform well in the second half of last year. Its financial results, though solid compared to similarly sized peers, were not always up to ...

The platform features Healthgrades, a tool intended to connect Alzheimer's patients to experienced local clinicians.

Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as ...

The tool will focus on educational resources by offering both in-person and telehealth support for individuals living in the ...

The company said its goal is to reduce wait times for patients seeking access to specialists, creating more opportunities for ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

Eli Lilly and Company (LLY) has expanded its LillyDirect digital healthcare platform to offer connections to independent in-person and telehealth options for people in the U.S. living with Alzheimer's ...

Investing in stocks remains one of the best ways to accumulate capital over long periods. Companies that can last -- and thrive -- that long are rare, but let's consider two brilliant examples ...

Lilly Meister lost her starting job, initially planning to step into Mackenzie Holmes' starting spot, but still played routine minutes. Her confidence has to be at an all-time high after a "spot ...

Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, approved by CDSCO, helps with weight management and activates hormone receptors.